Trial Information

Ofatumumab is designed to bind to the surface of some of the white blood cells (B-cells).
It may destroy cancer cells that come from B-cells.

Study Drug Administration:

If you are found to be eligible to take part in this study, you will receive a "loading
dose" (a lower dose given first, to lower the risk of a bad reaction to the study drug) of
ofatumumab by vein on Day 1 of Cycle 1. The loading dose is less than one-third (1/3) of
the normal dose. You will then receive the normal dose over 4 hours 1 time each week (+/- 3
days). The doses may be given more slowly, if your doctor thinks it is needed. All doses of
the study drug will be given at M. D. Anderson.

Benadryl (diphenhydramine) and glucocorticoids (steroids such as prednisolone) will be given
by vein 30 minutes to 2 hours before you receive ofatumumab to help prevent side effects.
You will also take pills of acetaminophen (Tylenol) to help prevent side effects. If no
side effects occur, these "pre-medications" may be reduced or not given after the second
infusion.

Study Visits:

One (1) time each week, before you receive ofatumumab:

- You will have a physical exam, including measurement of your vital signs.

- You will be asked about how you are feeling, about any side effects you may be having,
and about any changes in your health since the last visit.

- Blood (about 2 teaspoons) will be drawn for routine tests.

Length of Study:

You may continue taking the study drug until Day 50, as long as the doctor thinks it is in
your best interest. You will no longer be able to take the study drug if the disease gets
worse, if intolerable side effects occur, if you develop hepatitis B, or if you decide to go
off study.

End-of-Treatment Visit:

On the day of your last treatment or after you stop receiving the study drug for any
reason, the following tests and procedures will be performed:

- You will have a physical exam, including measurement of your vital signs.

- You will be asked about how you are feeling, about any side effects you may be having,
and about any changes in your health since the last visit.

- Blood (about 2 teaspoons) will be drawn for routine tests.

- If the doctor thinks it is needed, blood (about 2 teaspoons) will be drawn for
hepatitis testing.

Follow-Up:

About 3 months (+/- 2 weeks) after the end-of-treatment visit, the following tests and
procedures will be performed:

- You will have a physical exam, including measurement of your vital signs.

- You will be asked about how you are feeling, about any side effects you may be having,
and about any changes in your health since the last visit.

- You will have a bone marrow aspirate and biopsy, as well as CT scans of the chest,
abdomen, and pelvis, to check the status of the disease.

- Blood (about 2 teaspoons) will be drawn for routine tests.

- If the doctor thinks it is needed, blood (about 2 teaspoons) will be drawn for
hepatitis testing.

Every 3 months (+/- 4 weeks) after the end-of-treatment visit for 6 months:

- You will have a physical exam, including measurement of your vital signs.

- You will be asked about how you are feeling, about any side effects you may be having,
and about any changes in your health since the last visit.

- Blood (about 2 teaspoons) will be drawn for routine tests.

- If the doctor thinks it is needed, blood (about 2 teaspoons) will be drawn for
hepatitis testing.

Every year (+/- 4 weeks) after the end-of-treatment visit:

- You will have a physical exam, including measurement of your vital signs.

- You will be asked about how you are feeling, about any side effects you may be having,
and about any changes in your health since the last visit.

- Blood (about 2 teaspoons) will be drawn for routine tests.

- You will have a bone marrow aspirate and biopsy, as well as CT scans of the chest,
abdomen, and pelvis, to check the status of the disease.

This is an investigational study. Ofatumumab is FDA approved and commercially available for
use in the treatment of CLL. The use of ofatumumab as an early treatment for patients with
CLL/SLL who have not received other treatment is investigational.

Up to 44 patients will take part in this study. All will be enrolled at M. D. Anderson.

5. Patients must have adequate renal and hepatic function (creatinine <2mg/dL, total
bilirubin <2mg/dL). Patients with renal or liver dysfunction due to organ
infiltration with CLL may be eligible after discussion with the study chairman

6. Provide informed consent

7. Female patients (including those < 1 year post-menopausal) and male patients who have
not undergone previous surgical sterilization must agree to use contraception.

4. Positive serology for Hepatitis B virus (HB) defined as a positive test for HBsAg. In
addition, if negative for HBsAg but HBcAb positive (regardless of HBsAb status), a HB
DNA test will be performed and if positive, the patient will be excluded.

Type of Study:

Study Design:

Outcome Measure:

Number of Patients with Complete Response (CR)

Outcome Description:

Response assessment 3 months after last dose of Ofatumumab. 2008 International Workshop on CLL (IWCLL) update of the National Cancer Institute-sponsored Working Group (NCI-WG) outlined specific criteria of Complete Response (CR) for diagnosing CLL.

Outcome Time Frame:

3 months

Safety Issue:

No

Principal Investigator

William G. Weirda, MD, PhD, BS

Investigator Role:

Study Chair

Investigator Affiliation:

UT MD Anderson Cancer Center

Authority:

United States: Food and Drug Administration

Study ID:

2010-0241

NCT ID:

NCT01243190

Start Date:

March 2011

Completion Date:

Related Keywords:

Chronic Lymphocytic Leukemia

leukemia

small lymphocytic leukemia

SLL

CLL

ofatumumab

untreated

early stage

high-risk

Leukemia

Leukemia, Lymphocytic, Chronic, B-Cell

Leukemia, Lymphoid

Name

Location

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.